Research Article
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
Table 1
Characteristics of the studied population before treatment.
| | Characteristics | Studied group (n = 87) |
| | Qualitative variables (no., %) | | Gender | | | Male | 26 (29.9%) | | Female | 61 (70.1%) |
| | BMI | | | 18.5–24.9 | 20 (23%) | | 25.0–29.9 | 48 (55.2%) | | 30.0 and above | 19 (21.8%) |
| | Diabetes | | | Yes | 6 (6.9%) | | No | 81 (93.1%) |
| | Hypertension | | | Yes | 18 (20.7%) | | No | 69 (79.3%) |
| | Liver | | | Normal | 60 (69%) | | Cirrhotic | 27 (31%) |
| | Quantitative variables (mean ± SD) | | Age (years) | 50.18 ± 10.01 | | HCV RNA (copies/ml) | 925507 ± 1241001 | | Total bilirubin (mg/dl) | 0.88 ± 0.2 | | Serum albumin (mg/dl) | 4.32 ± 0.52 | | INR | 1.06 ± 0.08 | | AST (U/L) | 44.66 ± 18.2 | | ALT (U/L) | 49.2 ± 28.97 | | HB (g/dl) | 13.48 ± 1.4 | | Platelet (n × 103/μl) | 208.86 ± 66.02 | | Creatinine (mg/dl) | 0.9 ± 0.48 | | eGFR (ml/min per 1.73 m2) | 83.92 ± 20.18 | | FIB4 score | 1.7 ± 0.9 | | APRI score | 0.6 ± 0.39 |
|
|
BMI: body mass index; HCV RNA: hepatitis C virus-ribonucleic acid; INR: international normalization ratio; AST: aspartate aminotransferase; ALT: alanine aminotransferase; HB: hemoglobin; eGFR: estimated glomerular filtration rate; FIB4 : fibrosis four; APRI : AST to platelet ratio index.
|
